Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects
Lucerastat, an inhibitor of glucosylceramide synthase, has the potential to restore the balance between synthesis and degradation of glycosphingolipids in glycolipid storage disorders such as Gaucher disease a...
Source: Orphanet Journal of Rare Diseases - Category: Internal Medicine Authors: N. Gu érard, O. Morand and J. Dingemanse Source Type: research